Mayukh Sukhatme Sells 136,942 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 136,942 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $36.73, for a total value of $5,029,879.66. Following the completion of the transaction, the insider directly owned 18,630,739 shares of the company’s stock, valued at approximately $684,307,043.47. This trade represents a 0.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total transaction of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total transaction of $10,320,628.75.

Roivant Sciences Stock Up 0.1%

Shares of ROIV stock opened at $37.40 on Thursday. The company has a 50 day moving average price of $34.34 and a 200-day moving average price of $30.28. Roivant Sciences Ltd. has a 52 week low of $11.54 and a 52 week high of $37.97. The firm has a market capitalization of $27.01 billion, a PE ratio of -70.57 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. The firm had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. Analysts anticipate that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ROIV shares. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. HC Wainwright raised their price target on Roivant Sciences from $34.00 to $41.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Guggenheim upped their price objective on Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, Citigroup increased their target price on Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a report on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $35.14.

Institutional Trading of Roivant Sciences

Several large investors have recently added to or reduced their stakes in ROIV. Goldman Sachs Group Inc. raised its position in Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock worth $24,553,000 after acquiring an additional 324,764 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Roivant Sciences by 1.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after acquiring an additional 34,341 shares during the last quarter. American Century Companies Inc. grew its position in shares of Roivant Sciences by 1.9% during the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock valued at $1,010,000 after acquiring an additional 1,689 shares during the period. Russell Investments Group Ltd. grew its position in shares of Roivant Sciences by 149.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock valued at $129,000 after acquiring an additional 6,879 shares during the period. Finally, M&T Bank Corp increased its stake in shares of Roivant Sciences by 10.2% in the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after purchasing an additional 1,181 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.